Dear stakeholders,
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication for the 2ml presentation at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 12086 |
Project Team
| Project lead | Danielle Lees |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 April 2025 | Suspended. Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication for the 2ml presentation at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. |
| 21 February 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual